A comparison of liquid and solid culture for determining relapse and durable cure in phase III TB trials for new regimens.

about

A comparison of liquid and solid culture for determining relapse and durable cure in phase III TB trials for new regimens.

Item

http://www.wikidata.org/entity/Q46046130

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

A comparison of liquid and sol ...... II TB trials for new regimens.

@en

A comparison of liquid and sol ...... II TB trials for new regimens.

@nl

type

Item

label

A comparison of liquid and sol ...... II TB trials for new regimens.

@en

A comparison of liquid and sol ...... II TB trials for new regimens.

@nl

prefLabel

A comparison of liquid and sol ...... II TB trials for new regimens.

@en

A comparison of liquid and sol ...... II TB trials for new regimens.

@nl

P1476

A comparison of liquid and sol ...... II TB trials for new regimens.

@en

P2093

Andrew J Nunn

http://www.w3.org/2001/XMLSchema#string

Angela M Crook

http://www.w3.org/2001/XMLSchema#string

Anna Bateson

http://www.w3.org/2001/XMLSchema#string

Carl M Mendel

http://www.w3.org/2001/XMLSchema#string

Robert Hunt

http://www.w3.org/2001/XMLSchema#string

Timothy D McHugh

http://www.w3.org/2001/XMLSchema#string

P2860

Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications

A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP)

Geographic differences in time to culture conversion in liquid media: Tuberculosis Trials Consortium study 28. Culture conversion is delayed in Africa.

High-dose rifapentine with moxifloxacin for pulmonary tuberculosis.

Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis

Use of the BACTEC Mycobacteria Growth Indicator Tube 960 automated system for recovery of Mycobacteria from 9,558 extrapulmonary specimens, including urine samples

Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials.

Whole-genome sequencing to establish relapse or re-infection with Mycobacterium tuberculosis: a retrospective observational study.

High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.

Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resista

P2888

s12916-017-0955-9

P304

207

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12916-017-0955-9

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Patrick Phillips

Stephen H Gillespie

P577

2017-11-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1092927425

http://www.w3.org/2001/XMLSchema#string

P698

29169355

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial

P932

5701316

http://www.w3.org/2001/XMLSchema#string